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Globally, increasing acquired antimicrobial resistance among pathogenic bacteria presents an urgent challenge to
humanand animal health. As a result, significant efforts, such as theOneHealth Initiative, are underway to curtail and
optimize the use of critically important antimicrobials for humanmedicine in all applications, including food animal
production. This review discusses the rationale behind multiple and competing “critically important antimicrobial”
lists and their contexts as created by international, regional, and national organizations; identifies discrepancies
among these lists; and describes issues surrounding risk management recommendations that have been made by
regulatory organizations on the use of antibiotics in food animal production. A more harmonized approach to
defining criticality in its various contexts (e.g., for human versus animal health, enteric diseases versus other systemic
infections, and direct versus indirect selection of resistance) is needed in order to identify shared contextual features,
aid in their translation into risk management, and identify the best ways to maintain the health of food animals,
all while keeping in mind the wider risks of antimicrobial resistance, environmental impacts, and animal welfare
considerations.
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Introduction
The term antimicrobial refers to anything that
inhibits bacteria, viruses, fungi, or micropara-
sites. The term often is used synonymously with
antibiotic, although the latter specifically refers
to a microbial-derived compound that is active
against bacteria. Both terms are used interchange-
ably throughout the text here; in general—though
not exclusively—“antimicrobial” is used in conjunc-
tion with resistance, whereas “antibiotic” is used
when discussing a pharmacologically active agent.
In recent years, there have been increasing concerns
that the widespread use of antibiotics in food ani-
mal agriculture could lead to the emergence, spread,
and propagation of bacteria that are antibiotic resis-
tant. If these bacteria spread to human populations
through food products, direct contact with ani-
mals, or via the environment, the resulting infec-
tions could be more difficult to treat if antibiotics of
the same class or different classes of antimicrobials
are used in both animals and in human medicine,
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leading to increased burdens ofmorbidity andmor-
tality, and increased costs for care.1 To help navi-
gate the complex set of medications involved and to
ensure that the most essential drugs are used judi-
ciously in both human and veterinary medicine,
public and animal health organizations have created
competing lists of “critically important antimicro-
bials” (CIAs) that rank these compounds accord-
ing to their importance in human and veterinary
medicine, respectively.2
This article will discuss howCIAs are defined and
how international and national guidelines concern-
ing their use are developed. The following is based
on the presentations and discussions of the inte-
grated discussion group meeting “Minimizing the
Risk of Antimicrobial Resistance from Food Ani-
mal Production,” hosted by the New York Academy
of Sciences on May 8 and 9, 2018. The authors—
including veterinarians, microbiologists, epidemi-
ologists, physicians, economists, and food safety and
public health specialists—are from international
academic and industry organizations.
Defining critically important antimicrobials
Antimicrobial classification from a global
human and animal health perspective
Globally, despite arising fromapublic health agency,
the World Health Organization (WHO) CIA list
serves as the benchmark for food animal producers
around the world and provides important guidance
to global retail companies.2,3 The WHO CIA list is
the only one of its kind that considers global antimi-
crobial use and designates compounds as medi-
cally important if they have indications in human
medicine anywhere in the world, and regardless of
whether or not these are for infections caused by
enteric bacteria common to animals and humans.3
TheWHOpublished its first CIA list in 2005, and
the fifth and most recent revision was released in
20162 and the 6th revision (2018) was scheduled for
release in 2019. The 2016 list ranks antimicrobial
compounds into four categories:
1. “Critically Important,” which includes two
subcategories deemed “Highest Priority” and
“High Priority.” An antimicrobial designated
“Critically Important”mustmeet two criteria.
The first is defined as “the sole, or one of
limited available therapies, to treat serious
bacterial infections in people” (Criterion
1). In addition, those infections must either
“be transmitted to humans from nonhuman
sources” or have the potential to “acquire
resistance genes from nonhuman sources”
(Criterion 2). Finer distinctions are made
among the “Critically Important” antimicro-
bials, such as those with a “high frequency
of use,” a “high proportion of use in patients
with serious infections in health care settings,”
or else those used “to treat infections in people
for which there is evidence of transmission
of resistant bacteria or resistance genes from
nonhuman sources.” In turn, antimicrobials
meeting any of these distinctions earn the
designation “Highest Priority.”
2. “Highly Important” antimicrobials meet
either Criterion 1 or 2 listed above but not
both.
3. “Important” antimicrobials are any other
products used in human medicine, meeting
neither Criterion 1 nor 2.
4. “Currently not used in humans” is a category
that reappeared on the 2016 list for the first
time since 2005 and is listed in Annex 2 of the
2016 CIA.
The majority of antimicrobial classes on the
WHO CIA list fall within the “Critically Impor-
tant” category, with fewer classes in the “Highly
Important” category, fewer still in the “Impor-
tant,” and even fewer in the “Currently not used in
humans” categories (Fig. 1).2 The Critically Impor-
tant, Highly Important, and Important categories
are also referred to as “Medically Important Antimi-
crobials.” The “Currently not used in humans” cate-
gory is also referred to as “Non-medically Important
Antimicrobials.”
Separate from the WHO CIA list, the World
Organization for Animal Health (OIE) also cre-
ated a CIA list of antimicrobials that are impor-
tant in veterinary medicine. Although the hope
from the scientific community was that the most
important antimicrobialswouldnot beonboth lists,
there is considerable overlap between the WHO
and OIE lists.4 For example, macrolides, which
have always been considered “Critically Important”
on the WHO CIA list, were likewise placed in
the “Veterinary Critically Important Antimicrobial
Agents” (VCIA) category on the OIE list. However,
bacitracin, a cyclic peptide, is low on the WHO
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Figure 1. WHO list (5th revision, 2017) of critically important antimicrobials for human medicine. Adapted from Ref. 36.
CIA list (where it is classified as an “Important”
antimicrobial), while it is ranked on the OIE list
among the “Veterinary Highly Important Antimi-
crobial Agents” (VHIA).4 It should be noted that
the two organizations used different criteria and
goals to create their CIA lists, and in some instances
there may be a need for further clarification and
refinement in the interest of preventing antimicro-
bial resistance.
National and regional CIA lists
The WHO encourages countries and regions to
create their own CIA lists based on the antibi-
otics used for human health in their area.2 Specif-
ically, the WHO notes “that the implementation
of the concept at national levels required that
national considerations would be taken into
account, andconsequently listsmayvary fromcoun-
try to country . . . ”2 To ensure that the “national”
or “regional” context is taken into account, these
CIA lists should have precedence above other lists,
including the WHO list.
To date, countries, such as the United States,
Europe, Australia, and Japan, have country- or
region-specific CIA lists;5–8 meanwhile, other coun-
tries are currently developing CIA lists, includ-
ing China, Thailand, Malaysia, India, Philippines,
and New Zealand. It is important to note that the
national and regional CIA lists rarely are completely
aligned with the WHO CIA list. On the other hand,
such country-specific lists are essential to address
regional health priorities, resistance profiles, and
approved drug uses that cannot be captured on
a global scale. While this can create uncertainty
among retailers and companies that source ani-
mal products locally, as well as import and export
on a global scale, multinational companies deal
with a highly complex compliance environment
and are generally well equipped to deal with such
variability.
U.S. FDA lists
An equivalent to the WHO CIA list for the United
States is contained as Appendix A in FDA’s 2003
Guidance for Industry #152.8 Amuch-awaited revi-
sionwas anticipated to begin before the end of 2018,
but theprocessmay still take several years.Currently,
the FDA list, which is almost exclusively focused on
foodborne pathogens (rather than all bacterial dis-
eases of humans as per the WHO), includes three
categories:
1. “Critically Important” antimicrobials are
“used to treat enteric pathogens that cause
foodborne disease” (Criterion 1), and are the
“[s]ole therapy or one of few alternatives to
treat serious human disease or drug is essen-
tial component among many antimicrobials
in treatment of human disease” (Criterion 2).
2. “Highly Important” compounds meet either
Criterion 1 or 2.
3. “Important” compounds are used to “treat
enteric pathogens in nonfoodborne disease”
(Criterion 3), and/or are not associated
with “cross-resistance within drug class” or
“linked resistance with other drug classes”
(Criterion 4), and/or there is “[d]ifficulty
in transmitting resistance elements within
or across genera and species of organisms”
(Criterion 5).
The WHO (2016) and FDA (2003) lists agree
in that they both rank third-generation cephalo-
sporins, fluoroquinolones, and macrolides in the
“Critically Important” category.However, theWHO
later designated fourth-generation cephalosporins,
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glycopeptides (added in 2011), and polymyxins
(added in 2016) as “Critically Important,” whereas
the FDA categorized them in 2003 as only “Highly
Important.”2 A decision taken by the Veterinary
Medicines Advisory Committee (VMAC) of the
FDA in 2006 to recommend against approval
of a fourth-generation cephalosporin product
(cefquinome) for use in veterinary medicine sug-
gests that its risk management was not affixed
to 2003 data, which categorized fourth-generation
cephalosporins as highly important rather than crit-
ically important.9,10 Several other contrasts exist
between the WHO list, which designates pleuro-
mutilins and cyclic polypeptides (e.g., bacitracin)
as “medically important,” whereas the FDA consid-
ers the plueromutilins and bacitracin to be “non-
medically” important. In general, the rationale for
differences among lists can be discerned through
careful analysis of the regulatory process, stated pur-
poses of each list, and the specified criteria. The
effects on actual use and practice are much more
difficult to measure or predict.
Other regional and national CIA lists
In Europe, the European Medicines Agency (EMA)
released an antimicrobial ranking system in 2014,
which classified antimicrobials according to three
categories, whereby Category 1 poses the lowest risk
to human health and Category 3 poses the high-
est risk and is “not approved for use in veterinary
medicine.”7 As the EMA noted, Category 1 includes
certain antimicrobials that are considered “Criti-
cally Important” by the WHO, such as macrolides
and polymyxins, although somemacrolides are seen
as not critically important, based on their ring
structure.7
Similarly, the CIA list in Japan classifies
macrolides according to their ring structure.5
Fourteen- and fifteen-member macrolides are con-
sidered “Critically Important,” with the exception
of erythromycin, which is “Highly Important,”
whereas 16-membermacrolides, such as tylosin, are
deemed “Important.”
The Australian CIA list classifies macrolides as
being “low” for human and veterinary medicine,
which is a significant departure from other lists.6
Although Australia does not use fluoroquinolones
in animal agriculture, the country still has low levels
of fluoroquinolone-resistant Campylobacter (espe-
cially when compared to Europe, South America,
and most of the world except Canada and the
United States); as a result, it is currently trying to
understand the source of these resistant bacteria.11
Besides the macrolides, other notable differences
between the Australian CIA and the WHO CIA
include the ketolides and penicillins, which are
“Critically Important” under theWHO criteria, but
of “Low” importance under the Australian Impor-
tance Ratings. The difference in importance rating
reflects the relatively low reliance on these antibac-
terials in Australia because resistance is widespread
in many human pathogens causing infection in
Australia. Although the rating for streptogramins
has been reduced from “Critically Important” to
“Highly Important” in the latest iteration of the
WHO List, they remain in the highest category
(high) in the Australian Importance Ratings. This
is because pristinamycin is a reserve agent used for
methicillin-resistant Staphylococcus aureus infection
in Australia.6
Given the different antibiotic treatment practices
used in human medicine around the world, the dis-
connect between the WHO CIA list and the var-
ious national and regional lists seems inevitable.
While each local CIA list is helpful from the per-
spective of human medicine, taken together they
could potentially create difficulties when it comes
to the trade ofmeat and livestock between countries
with discrepant CIA lists. Indeed, there is anxiety in
Latin American and Asian countries that they will
be required to abide by the recommendations of
countries they export to. To this end, the European
parliamenthas recently proposed a resolution toban
the import of meat from countries that use antibi-
otic growth promoters, although the resolution was
not approved.
Going forward, it is expected that the WHO, as
well as national CIA lists, will be revised every 2–3
years. It will be unusual for a list to not be updated
for 15-plus years, as is the case with the FDA GFI
152 Appendix A.8 This fluidity will help keep these
lists up to date, but could present challenges for
food animal producers. For example, an antibiotic
that played a key part in an animal health man-
agement system could be upgraded in importance
because it was found to select for bacterial resistance
after a resistance gene arose, which can occur with-
out warning.12 Generally speaking, the uses of those
antibiotics that are revised upward as to their criti-
cality are restricted in turn from prevention (which
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is disallowed in many countries already) through
disease control and finally to treatment. It is rare
that antibiotic use for the treatment of infected and
clinically ill animals is completely restricted; how-
ever, it remains an option especially for the class
of highest priority CIAs.13,14 Meanwhile, veterinar-
ians in large food animal production companies are
urging that antimicrobials that are used in human
medicine but do not pose a threat for resistance,
such as bacitracin, be granted protected status as
safe for animal use.8
Factors affecting antibiotic use in animal
agriculture
Several factors affect which antibiotics and how
much of them are used in animal agriculture. Global
and national regulations play an important role; but
self-imposed limitations within the private sector
are also meaningful factors.
WHO recommendations for antimicrobial use
in agriculture
In 2017, theWHOpublished fourbroad recommen-
dations on the use of medically important antimi-
crobials in food animal production in order to
maintain effectiveness of these antimicrobials in
human medicine.3 To develop the basis for its rec-
ommendations, theWHO commissioned two inde-
pendent systematic reviews, the first of which was
published in Lancet Planetary Health in 2017.1,15
The review concluded that interventions aimed at
reducing antibiotic use in food-producing animals
were associated with reduced antibiotic resistance
in these animals, but there was less compelling evi-
dence that these interventions also reduced antibi-
otic resistance in human populations.
The first WHO recommendation calls for an
“overall reduction in use of all classes of medi-
cally important antimicrobials in food-producing
animals.” Similarly, the second recommendation
calls for the “complete restriction of use of all
classes of medically important antimicrobials in
food-producing animals for growth promotion.”
Those two recommendations were well received
by experts in the food-animal industry, particu-
larly in the United States, where the FDA had
already achieved a de facto ban on the use of med-
ically important antibiotics for growth promotion
in 2017 through voluntary withdrawal of labels by
drug sponsors.
By contrast, Recommendation 3—which calls for
the “complete restriction of use of all classes ofmed-
ically important antimicrobials in food-producing
animals for prevention of infectious diseases that
have not yet been clinically diagnosed”—has been
rejected outright by many.16,17 The main issue with
this recommendation seems to be that there is no
universally accepted definition of what is meant by
prevention, as organizations each defines preven-
tion in different ways and adds to the confusion.
Nevertheless, on November 30, 2018, a major U.S.
poultry producer committed to achieving the equiv-
alent of the thirdWHOGuideline recommendation
by March 2019 by removing its use of gentamicin
and virginiamycin from its prevention protocols.18
Recommendation 4 from the WHO, which is
a two-part recommendation, is widely viewed
as highly controversial.16,19,20 Recommendation 4a
states that antimicrobials classifiedbyWHOas “crit-
ically important for human medicine ( . . . ) should
notbeused for control of thedisseminationof a clin-
ically diagnosed infectious disease identified within
a groupof food-producing animals.”Recommenda-
tion 4b states that antimicrobials that are the “high-
est priority critically important for humanmedicine
should not be used for treatment of food-producing
animals with a clinically diagnosed infectious dis-
ease.” These latter two recommendations (4a and
4b) are supported by the lowest quality of evidence
(per GRADE criteria) and are not strongly made by
WHO (in contrast to Recommendation 3).21
The Chief Scientist of the U.S. Department of
Agriculture (USDA) denounced these recommen-
dations, stating they would “impose unnecessary
and unrealistic constraints” on veterinarians’ pro-
fessional judgment to treat, control, and prevent
disease.16 The USDA also condemned the recom-
mendations for being unsupported by sound data
and out of alignment with U.S. policy.16 Simi-
larly, the American Veterinary Medical Association
(AVMA) criticized the recommendations as putting
“unwarranted restrictions” on antibiotic use for
protecting animal health and the food supply.17
Both the USDA and AVMA pointed out that the
WHO developed the recommendations based on
evidence that was by the WHO’s own assessment
of “low-quality” (Recommendations 1–3) and
“very low-quality” (Recommendations 4a and
4b). However, the systematic review on which
the recommendations were primarily based could
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only analyze available observational studies (cross-
sectional and longitudinal) that are by definition
low quality according to the WHO grading system
(GRADE). Some critics have suggested that the
WHO change its grading system so that the types
of studies needed here, which are not conducive to
randomized trials, can be graded as being of higher
quality. However, the philosophy at theWHO tends
toward preemptive action, which leads to more
cautious recommendations. Within this context,
researchers are currently evaluating the grading
system and the studies on which Recommendations
3 and 4 were based.
Clearly, there needs to be a more universally
recognized definition of prevention. Equally impor-
tant is a more universally accepted set of guidelines
concerning prevention uses of medically important
antibiotics, especially where alternative means of
reducing the risk of disease are known to exist.
McDonald’s, in its 2015 Global Antibiotic Policy
on stewardship, attempts to differentiate between
“routine prevention” and “targeted prevention.”22
It would be appropriate that producers shift from
using antimicrobials for routine prevention and
instead identify critical life stages, or a set of
risk factors, for when preventive use is justified.
For instance, restricting antibiotic use to defined
periods when animals are more vulnerable to
infection because they are stressed or their immune
systems are depressed, such as when chicks are
moved into houses or when piglets are weaned.
Alternatives to antibiotics, especially for prevention
indications, are currently a topic of great interest
to advocates, industry, and researchers.23 Notably,
the WHO and many organizations do not currently
distinguish between disease prevention, which
is treating animals that do not have detectable
pathogens but are at risk of being infected, and
disease control, which involves treating groups of
animals with varying numbers of detectable but
often subclinical infections.3
U.S. regulatory framework
FDA regulations have also led to a reduction in
domestic sales of antibiotics in animal agriculture,24
most notably through the FDAGuidance for Indus-
try (GFI) 213 which called for the voluntary
withdrawal of labels of medically important
antibiotics used for growth promotion (AGP)
in food animals.25 As of January 1, 2017, the
FDA prohibited the use of medically important
antibiotics for AGP, though a staged withdrawal of
labels by sponsors was initiated over the previous
3-year period and resulted in drastic reductions in
the options available to producers. There remains
a need for improved communication by the FDA
about antibiotic practices that are permitted,
including dosing and administration. While “over-
the-counter” formulations of in-feed and in-water
antibiotics for food-producing animals have
completely disappeared, veterinarians have been
afforded a much greater role in decision making
through Veterinary Feed Directives. However, the
agency has approved new uses of medically impor-
tant antibiotics in animal agriculture that appear
counterintuitive to the goal of reducing antibiotic
use. For example, a long-duration formulation of
the third-generation cephalosporin ceftiofur is now
labeled as requiring 2 doses 3 days apart, effectively
doubling the mass of active ingredient used to
treat metritis in dairy cows.26,27 This approval
was announced soon after the extra-label use of
cephalosporins in food-producing animals was
prohibited, albeit with several exceptions.28 Further,
the agency has recently approved “control” labels
for the fluoroquinolone enrofloxacin, opening the
door to mass treatment (control) of groups of cattle
and pigs to control respiratory disease.29
It should be noted that a number of countries
have adopted the FDA model on the use of AGPs
(e.g., Australia and Malaysia), and following a risk
assessment approachhave chosen toonlyban theuse
of medically important antibiotics as AGPs. Other
countries (e.g., New Zealand and Thailand) have
taken amore precautionary approach, similar to the
EU, and banned the use of all antibiotics for AGP
use.
Assessing antibiotic use in animal
agriculture
Historically, assessing the quantities and types of
antibiotics that are used in animal agriculture has
been challenging, which has made it very difficult
to understand the effects of policies on antibiotic
use. Antimicrobial drug sponsors are now required
by the FDA to estimate the sales volume/mass of
antimicrobials to each of the major food animal
commodities (cattle, swine, chickens, and turkeys)
to which they sell in the United States.30 This
policy is aimed at tracking how drugs are used in
13Ann. N.Y. Acad. Sci. 1441 (2019) 8–16 C© 2019 The Authors. Annals of the New York Academy of Sciences
published by Wiley Periodicals, Inc. on behalf of New York Academy of Sciences.
Guidelines for reducing antibiotic use in food animals Scott et al.
Figure 2. Domestic sales anddistribution of antimicrobial drugs approved for use in food-producing animals in 2016. Reproduced
from U.S. FDA 2016 Summary Report.
1Includes antimicrobial drug applications, which are approved and labeled for use in both food-producing
animals (e.g., cattle and swine) and nonfood-producing animals (e.g., dogs and horses).
2kg = kilogram of active ingredient. Antimicrobials, which were reported in International Units (IU) (e.g., penicillins), were
converted to kg. Antimicrobial class includes drugs of different molecular weights, with some drugs reported in different salt forms.
3Guidance for Industry #213 states that all antimicrobial drugs and their associated classes listed in Appendix A of FDA’s Guidance
for Industry #152 are considered “medically important” in human medical therapy.
4Not Medically Important refers to any antimicrobial class not listed in Appendix A of FDA’s Guidance for Industry #152.
5NIR=Not Independently Reported. Antimicrobial classes for which there were fewer than three distinct sponsors activelymarket-
ing products domestically are not independently reported. These classes include the following: amphenicols, diaminopyrimidines,
polymyxins, and streptogramins.
6NIR=Not Independently Reported. Antimicrobial classes for which there were fewer than three distinct sponsors are not indepen-
dently reported. These classes include the following: aminocoumarins, glycolipids, orthosomycins, pleuromutilins, polypeptides,
and quinoxalines.
veterinary medicine. These estimates are not likely
to be precise, since the companies have little control
over how drugs are actually used and for which
indications. Animal health pharmaceutical compa-
nies have relations with their clients that currently
permit reasonable estimates of sales to the target
food animal species, if not for specific disease indi-
cations. As the data from veterinary feed directives
(i.e., prescriptions) accumulate in the private sector,
it is hoped that more refined estimates will be forth-
coming regarding species-specific sales data.31,32
In addition, this means that sales data rather than
usage data are used to infer antibiotic use; sales
data are less exact, lack geographical specificity,
and do not include information on companion
animals. However, this is currently the best quality
information on how antimicrobials are being used
in food animal agriculture in the United States.
While not ideal this is progress, since prior to this
amendment data were aggregated across all species.
In the United States, domestic sales of all antimi-
crobial drug classes licensed for use in food-
producing animals in the United States decreased
by 10% from 2015 to 2016, after steadily increas-
ing from 2009 to 2015, according to an FDA 2016
Summary Report.24 Over this period, two antimi-
crobial classes have dominated sales in the United
States for food-producing animals in terms of total
weight (kilograms) of drug for primarily domestic
sales of: (1) ionophores (not medically important),
which are predominantly sold for use in cattle and
chickens; and (2) tetracyclines, which are primar-
ily sold for use in cattle and swine and are con-
sidered medically important.24 Figure 2 shows the
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sales data for each of the antimicrobial classes from
2016. Notably, the antibiotics most commonly used
in human medicine, such as -lactam antibiotics
including cephalosporins and penicillin, make up
less than 10% of sales by mass in food-producing
animals.33
Other FDA requirements pertaining to how
antibiotics must be administered may actually drive
up drug use in practice. For example, a recent study
found that intermittent feeding of tylosin achieves
reduction of liver abscesses in cattle comparable to
continuous feeding, but this strategic antibiotic use
may violate laws governing specific use practices.34
Given the regulations on antibiotic use, veterinari-
ansmay be required to administer higher doses than
they feel is necessary, or for longer than needed, to
prevent disease.35
Conclusions
In order to prioritize and protect the most essen-
tial antibiotics used in human medicine, the WHO
and national governments have created CIA lists.
Competing lists for animal health also exist at sim-
ilar scales and serve to prioritize antibiotics among
the range of acceptable uses in food animal agri-
culture. Additional recommendations and regula-
tions have been put in place to curtail the use
of antibiotics, which have helped to reduce the
use of antimicrobial use in food animal produc-
tion. However, more data are needed to better
understand how antimicrobials are used in ani-
mal agriculture to find opportunities for further
reduction. Additional research into alternatives to
antibiotics in order to prevent disease, coupled with
more judicious use of antibiotics needed to treat
and control infectious diseases in food animals, is
necessary.
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